Clinical Trial Update: GTX-RT in Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of GTX-RT for borderline resectable pancreatic cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• GTX-RT

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-08-13